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Summary
Background.— Hypertension is both the cause and consequence of chronic renal failure (CRF).
The prevalence of CRF, which itself is a cardiovascular risk factor, is not well known in France.
Aims.— To estimate the prevalence of renal dysfunction among hypertensive patients who were
seen by general practitioners (GP); to assess the drug management of hypertension in these
patients according to their renal status.
Methods.— A transversal observational study among patients of both genders aged 18 or more,
with arterial blood pressure greater than 130/80mmHg (i.e., over CRF-recommended blood
pressure) or under antihypertensive drugs who were recruited in France by GP.
Results.— Among the 2315 included patients, 1908 could be analyzed for their renal function.
Of these, 70.5% had an estimated glomerular ﬁltration rate (GFR) of 89ml/min per 1.73m2 or
lower. One third of these patients (31.4%) were suffering from renal failure (GFR≤ 59ml/min per
1.73m2). CRF was moderate in 27.9% of patients, severe in 2.20% and terminal (GFR < 15ml/min
per 1.73m2) in 1.26%. At least one antihypertensive drug was taken by 1952 patients (84.3%),
regardless of the patient’s renal status.
Conclusion.— Hypertensive patients who are seen by GP have a high level of renal disturbances
and many of them do not reach recommended blood pressure values. This highlights the
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MOTS CLÉS
Insufﬁsance rénale
chronique ;
Hypertension ;
Inhibiteur de
l’enzyme de
conversion ;
Antagoniste des
récepteurs de
l’angiotensine 2 ;
Protéinurie ;
Microalbuminurie
recommandés. Ces résultats soulignent l’importance d’un dépistage précoce d’un dysfonction-
nement rénal évitant la progression vers l’IRC terminale et celle d’une prescription adaptée
d’antihypertenseurs inhibiteurs de l’enzyme de conversion et antagonistes des récepteurs de
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ntroduction
he incidence rates of chronic renal failure (CRF) are con-
tantly increasing in France and in the developed world. In
006, the French Renal Epidemiology and Information Net-
ork (REIN) reported that 6509 patients with end-stage renal
isease from 16 French regions covering 79% of the popula-
ion had begun initial renal replacement therapy (RRT) for
RF (dialysis or graft) [1]. The asymptomatic or poorly symp-
omatic nature of renal dysfunction explains why it is often
iscovered at a very late or even terminal stage, requiring
rgent RRT and resulting in a much less favorable prognosis
han if the RRT had been properly prepared.
Arterial hypertension (AH) is both the cause and the
lmost inevitable complication of CRF [2]. Hypertension
ncreases the risk of complications in CRF patients and,
ndependent of the etiology of renal failure, speeds up the
eterioration of renal function. It also favors the early onset
f cardiovascular complications, accelerates the progres-
ion of cardiovascular lesions and increases early mortality.
atients with renal failure often have isolated systolic hyper-
ension with a normal or low diastolic pressure. It is systolic
ressure which best indicates the risk of progression towards
nd-stage renal failure. Furthermore, it has been shown that
enal failure is an important risk factor for all-cause and
ardiovascular mortality [3].
Since 2003, numerous recommendations have been pub-
ished pertaining to blood pressure targets in the case of CRF
o
t
f
a
ant des effets néphroprotecteurs.
sson SAS.
4—8]. Thus, according to international recommendations of
NC VII followed by ANAES [4], the target blood pressure in
enal failure patients should be 130/80mmHg.
The adequate control of arterial blood pressure is rec-
gnized to be an essential factor in slowing down the
rogression of CRF. However, screening for renal failure is
ot routine in the case of hypertension [9,10]. Given the
ole of hypertension in the progression of CRF, we considered
t important to examine the distribution of hypertensive
atients according to their renal disease stage and the man-
gement of their hypertension. This survey was conducted
ver the course of 1week in patients from all over France
ho consulted their general practitioner (GP) presenting
ith blood pressure greater than or equal to 130/80mmHg
nd/or who were undergoing antihypertensive therapy.
aterial and methods
his national and transversal observational study conducted
ver 1week concerned patients recruited consecutively in
ll of France by a representative sample of GP. The survey
as conducted in accordance with legal requirements. The
P were chosen at random from a comprehensive databaseA. P.-Guérin et al.
importance of an early detection of renal dysfunction avoiding progression towards end-stage
renal failure and an adapted antihypertensive drugs prescription, such as angiotensin-converting
enzyme inhibitors and angiotensin receptor blocker, acting as renal protectors.
© 2008 Published by Elsevier Masson SAS.
Résumé
Introduction.— L’hypertension artérielle est à la fois la cause et la conséquence de
l’insufﬁsance rénale chronique (IRC). La prévalence de l’IRC, elle-même facteur de risque
cardiovasculaire majeur, est mal estimée en France.
Objectifs.— Estimer la prévalence de l’atteinte rénale chez des patients hypertendus vus
en consultation de médecine générale ; évaluer la prise en charge médicamenteuse de
l’hypertension des patients inclus en fonction de leur statut rénal.
Méthodes.— Étude observationnelle transversale chez des patients adultes présentant une
pression artérielle supérieure ou égale à 130/80mmHg (i.e., dépassant les objectifs tensionnels
pour l’IRC) ou prenant un traitement antihypertenseur, recrutés en France par des médecins
généralistes.
Résultats.— La fonction rénale de 1908 sur 2315 patients inclus dans l’étude a été analysée
et 70,5 % avaient un débit de ﬁltration glomérulaire (DFG) estimé inférieur ou égal à
89ml/min/1,73m2. Un tiers des patients (599 sur 1908 = 31,4 %) souffraient d’une atteinte
rénale (DFG≤ 59ml/min par 1,73m2). L’IRC était modérée chez 27,9 % des patients, sévère
chez 2,20 % des patients et terminale chez 1,26 % des patients. Au total, 1952 patients (84,3 %)
prenaient au moins un traitement antihypertenseur, quel que soit leur statut rénal.
Conclusion.— La population hypertendue vue en médecine générale présente une prévalence
des troubles rénaux élevée et n’atteint pas, pour une grande part, les objectifs tensionnelsf French GP and were stratiﬁed ﬁrst by region, then by
elephone interview. Inclusion criteria for patients were the
ollowing: patients of both genders, aged 18 years or more
nd presenting with a systolic blood pressure (SBP) and/or
diastolic blood pressure (DBP) greater than or equal to
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130/80mmHg or undergoing antihypertensive therapy. The
threshold of 130/80mmHg refers to the target blood pres-
sure recommended in the case of renal failure [4], so as to
identify those hypertensive patients presenting with kidney
problems.
For each patient, the GP collected in a registry demo-
graphic (sex, age, weight, height), clinical data (SBP/DBP:
GP were asked to record the second of two blood pres-
sure readings at an interval of a few minutes) the duration
of hypertension, serum creatinine, current antihypertensive
treatments and ﬁnally, metabolic and environmental data
concerning the patient’s cardiovascular, renal and diabetic
status.
The body mass index (BMI =weight/height2) and the body
surface area [BSA = (weight× height/3600)0.5] [11] were cal-
culated a posteriori. The glomerular ﬁltration rate (GFR) was
calculated on the basis of serum creatinine (mol/l), age
and weight using the Cockroft and Gault formula [12]. The
GFR was scaled to the BSA [13].
For the purposes of this study, the ANAES classiﬁca-
tion criteria for chronic renal disease and its severity were
used [13]: moderate renal failure (GFR between 30 and
59mL/min per 1.73m2), severe renal failure (GFR between
15 and 29mL/min per 1.73m2) and end-stage renal failure
(GFR < 15mL/min per 1.73m2). Patients with a GFR between
60 and 89mL/min per 1.73m2 presenting with renal disease
markers for more than 3months were considered to have
chronic kidney disease.
Statistical analysis
The statistical analysis was performed using SAS 9.1 (SAS
Institute, Cary, NC). The quantitative data are presented
as the number of patients (n), mean± standard deviation,
median and range. The qualitative data are presented as the
number of patients (n) and as percentages of the total data
set. Missing data were not treated in any special manner.
Group comparisons were conducted using the following
tests: Student’s t-test, ANOVA, Kruskal-Wallis, Chi-square
test and Fisher’s exact test. Furthermore, the Chi-square
test for trend was used for the analysis of the relation
between a categorical variable reﬂecting a grading (such
as the degree of renal failure) and a nominal variable with
two states (such as medical history). A P-value of < 0.05 was
considered statistically signiﬁcant.
Results
Patient characteristics
The demographic and clinical patient characteristics are
shown in Table 1. A total of 2315 (49.4% male), with a
mean age of 65± 13.6 years were recruited by 202 GP from
4 to 10 June 2007. The mean BMI was 27.5± 5.47 and 896
patients (39.8%) were overweight (25≤ IMC < 30) and 596
(26.5%) were obese (BMI≥ 30). The mean values for SBP and
DBP were 145± 12.2 and 84.5± 8.65mmHg, respectively.
The median duration of hypertension was 8.0 years.
Median serum creatinine, measured in 1959 patients, was
80mol/L (CI 95%: 85—92) and median GFR of 72.5 (CI 95%:
p
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14—137). The serum creatinine was higher in men (median:
8mol/L) than in women (median: 76mol/l) (p < 0.001).
he median GFR was 78mL/min per 1.73m2 in men versus
7 in women (P < 0.001). Likewise, the serum creatinine and
FR differed according to age (median serum creatinine in
icromole per litre — 18≤ age < 40: 78; 40≤ age < 60: 79;
ge≥ 60 years: 82 ; P < 0.001; median GFR in millilitre per
inute per 1.73m2 — 18≤ age < 40: 103; 40≤ age <60: 90;
ge≥ 60 years: 63 ; P < 0.001).
The study of hypertension risk factors according to HAS
ecommendations [7] shows, that in 85% of men and 66.2%
f women included in the study, age was a risk factor. In
ddition, 35.2% of patients had a cardiovascular family his-
ory, 21.4% were diabetic, 48.6% of patients presented with
yslipidemia current or past and 29.6% were smokers or
xsmokers.
We also compared the characteristics of patients having a
eported serum creatinine value (‘‘creatinine group’’, n = 1
59) with those without (‘‘non-creatinine group’’, n = 356).
verall, it seems that the age-related pathologies and cri-
eria were more common in the ‘‘creatinine group’’. It is of
ote that more patients in the ‘‘creatinine group’’ took at
east one ACE inhibitor or an A2RB, which could be explained
y the fact that renal failure had been detected in these
atients (results not shown).
valuation of renal function
able 2 shows the prevalence of each renal disease stage
mong the ‘‘creatinine group’’ — the GFR was able to
e calculated in 1908 patients — along with the percent-
ges of patients presenting with renal disease markers. Of
hese, 1345 patients (70.5%) had a GFR less than or equal
o 89mL/min per 1.73m2. The percentage of patients pre-
enting with chronic kidney disease was 1.47%. Furthermore,
he prevalence of patients presenting with kidney damage
as 31.4%. In this cohort, 27.9% (n = 533) had moderate
enal failure, 2.20% (n = 42) had severe renal failure and
.26% (n = 24) showed end-stage renal disease. In addition,
hen assessing renal disease markers, microalbuminuria was
etected in 14.6% and proteinuria in 9.6% of cases.
herapeutic management of hypertension
ccording to the renal disease stage
n total, 1952 out of 2315 (84.3%) patients took at least
ne antihypertensive drug. Focusing on patients with renal
ailure (DFG≤ 59mL/min per 1.73m2) reveals that:
among 550 patients (91.8%) treated for AH, 42 out of 544
(7.7%; six patients had incomplete blood pressure data)
had good blood pressure control and 502 out of 544 (92.3%)
had poor blood pressure control;
in 49 cases (8.2%), blood pressure was neither treated nor
controlled.
Patient groups deﬁned by their renal disease stage
iffered according to whether or not they had taken antihy-
ertensive medication (P = 0.002), the proportion of patients
aking at least one drug increased with the severity of the
enal disease (Chi-square test for trend, P < 0.001) (Table 3).
Regardless of renal status, the majority of patients took
etween one and two antihypertensive drugs (e.g., mean
708 A. P.-Guérin et al.
Table 1 Demographic and clinical characteristics of patients.
n n = 2315
Men 2313 1143 (49.4)
Age (years) 65.0± 13.6
Patients≥ 75 years 647 (27.9)
Men > 50 years 972 (85.0)
Women > 60 years 775 (66.2)
Body mass index (kg/m2) 2253 27.5± 5.47
Body surface area (m2) 2253 1.88± 0.22
SBP (mmHg)
Mean± S.D. 2303 145± 12.2
Median 142
Range 80—223
DBP (mmHg)
Mean± S.D. 2290 84.5± 8.65
Median 85
Range 50—142
Duration of hypertension (years) 2131 8
Serum creatinine (mol/L)
Mean± S.D. 1959 89± 78
Median 80
Range 1—93
CI 95% [85; 92]
Glomerular ﬁltration rate (mL/min per 1.73m2)
Mean± S.D. 1908 126± 263
Median 72.5
Range 5.05—6905
CI 95% [114; 137]
History of renal disease 116 (5.01)
Family history of renal disease 88 (3.80)
Cardiovascular family history* 816 (35.2)
Left ventricular hypertrophy documented by
ECG 84 (3.63)
Ultrasonography 113 (4.88)
ECG+ultrasonography 174 (7.52)
Dyslipidemia**
Currently 885 (38.2)
History 240 (10.4)
Current diabetes 495 (21.4)
Duration of diabetes (years) 441 9
Type of diabetes
Type 1 493 52 (10.5)
Type 2 404 (81.9)
Other type 37 (7.51)
Tobacco smoking
Currently 303 (13.1)
History 383 (16.5)
Data are expressed in n (%), median or mean± standard deviation (S.D.).
* Myocardial infarction or sudden death before the age of 55 years in the father or any other male ﬁrst-degree relative, myocardial
infarction or sudden death before the age of 65 years in the mother or any other female ﬁrst-degree relative, early CVA (< 45 years)
** LDL cholesterol greater than 1.60 g/L (4.1mmol/L), HDL cholesterol less than or equal to 0.40 g/L (1mmol/L) for both genders.
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Table 2 Prevalence of renal function disorders in patients with measured serum creatinine.
Stage of chronic kidney disease in patients with measured GFR
Stage of chronic kidney disease
No renal involvement (n = 1908)
GFR≥ 90 563 (29.5)
GFR≥ 90 or 60≤GFR< 89 with no renal disease markers during more than 3months 1281 (67.1)
Renal involvement (n = 1908)
GFR≤ 89 1345 (70.5)
60≤GFR≤ 89 with renal disease markers during more than 3months (chronic kidney disease) 28 (1.47)
GFR≤ 59 599 (31.4)
30≤GFR≤ 59 (moderate renal failure) 533 (27.9)
15≤GFR≤ 29 (severe renal failure) 42 (2.20)
GFR < 15 (end-stage renal failure) 24 (1.26)
Renal disease markers in patients with measured serum creatinine
Microalbuminuria (n = 1959)a 286 (14.6)
Proteinuria (n = 1959)b 188 (9.6)
Pathological hematuria (n = 1959)c 80 (4.1)
Pathological leukocyturia (n = 1959)d 70 (3.6)
Morphological abnormalities at renal ultrasonography (n = 1959)e 76 (3.9)
Data are expressed in n (%). GFR: glomerular ﬁltration rate (mL/min per 1.73m2).
a Microalbuminuria: 20—200g/min or 30—300mg per 24 h, albuminuria/creatininuria ratio greater than 2mg/mmol.
b 300mg per 24 h, proteinuria/creatinemia ratio greater than 200mg/g.
c Erythrocytes greater than 10/mm3 or 10,000/mL.
d Leukocyturia: leukocytes greater than 10/mm3 or 10,000/mL.
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for moderate CRF = 1.66± 0.97). Of the 1908 patients, 240
(12.6%) did not take any antihypertensive medication, 879
(46.1%) took one antihypertensive drug, 522 (27.4%) took
two and 267 (14.0%) took at least three antihypertensive
drugs.
Of the patients with severe renal failure, 66.7% took
at least one diuretic, 31.0% at least one ACE inhibitor
and 31.0% at least one A2RB. Among the patients with
end-stage renal failure, 45.8% took at least one diuretic,
16.7% at least one ACE inhibitor and 37.5% at least one
A2RB. Overall, the distribution of patients according to their
renal disease stage differed according to the prescribed
treatment and the percentage of patients treated tended
to increase with the severity of renal disease. This was
true for all treatments except for patients who took at
least one A2RB or at least one -blocker (Table 3). Fur-
thermore, the number of patients taking at least one ACE
inhibitor tended to increase with the severity of renal dis-
ease (P = 0.061).
Fig. 1 illustrates the management of microalbuminuria
and/or proteinuria, with or without diabetes, in patients
with renal failure, using ACE inhibitors and/or A2RB. In total,
32.3% of diabetics with proteinuria, 23.2% of diabetics with
microalbuminuria, 29.6% of diabetics with both proteinuria
and microalbuminuria, 37% of patients with proteinuria but
without diabetes and 28.2% of patients with microalbumin-
uria without diabetes took neither ACE inhibitor nor A2RB.
Conversely, 6.5% of diabetics with proteinuria, 5.8% of dia-
betics with microalbuminuria, 7.4% of diabetics with both
proteinuria and microalbuminuria, 3.7% of patients with pro-
teinuria but without diabetes and 2.6% of patients with
d
A
l
Tic kidneys, nephrocalcinosis, calculus, hydronephrosis.
icroalbuminuria but without diabetes took one ACE along
ith an A2RB.
iscussion
his survey aimed to update data concerning the prevalence
f renal dysfunction by taking into account the different
tages of CKD and CRF as proposed by ANAES and to describe
he therapeutic management of these patients in an ever-
hanging environment. Our study population, selected on
he basis of criteria linked to AH (blood pressure over
30/80mmHg and/or treatment with antihypertensive med-
cation), is relatively old (65.0± 13.6 years) and made up of
s many men as women. Our results are in line with those
f previous studies which showed that renal function dete-
iorates progressively with age [9,14,15]. Moreover, while
e observed that serum creatinine and GFR were higher in
en than in women, a study of 2100 hypertensive patients
ecruited by cardiologists in private practice showed that
enal failure began signiﬁcantly earlier and was more severe
n women than in men, while after the age of 70, there
as no longer any difference between the two groups [9].
n this study, the mean age of patients (65.9± 12.2 years)
nd the mean duration of antihypertensive treatment were
omparable to those observed in our study.We found that 1023 patients (44.2%) had consulted a car-
iologist, whereas only 144 (6.2%) had seen a nephrologist.
ll around the world, patients suffering from renal failure
eave it too late before consulting a nephrologist, if at all.
his problem of ‘‘late referral’’ seems very common and
710
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Table 3 Analysis of antihypertensive treatments according to the stage of chronic kidney disease (blood pressure greater or equal to 130/80mmHg, n = 1908).
Chronic renal failure
(0) No renal
involvement
(1) Chronic kidney
disease GFR≥ 60
(2) Moderate
renal failure
(3) Severe
renal failure
(4) End-stage
renal failure
P P-trend
n = 1281 n = 28 n = 533 n = 42 n = 24
Number of treatments
Mean± S.D. 1.33± 0.89 2.04± 1.23 1.66± 0.97 2.21± 1.20 1.63± 1.06
0 (n = 240) 189 (14.7) 2 (7.1) 44 (8.3) 3 (7.1) 2 (8.3) — —
1 (n = 879) 635 (49.6) 9 (32.1) 214 (40.1) 10 (23.8) 11 (45.8) — —
2 (n = 522) 321 (25.1) 7 (25.0) 176 (33.0) 11 (26.2) 7 (29.2) — —
≥ 3 (n = 267) 136 (10.6) 10 (35.7) 99 (18.6) 18 (42.9) 4 (16.7) — —
Treatments
≥ 1 treatment with ACE
inhibitor (n = 439)
273 (21.3) 12 (42.9) 130 (24.4) 13 (31.0) 4 (16.7) 0.028 0.061
≥ 1 treatment with A2RB
(n = 772)
508 (39.7) 11 (39.3) 215 (40.3) 13 (31.0) 9 (37.5) 0.830 —
≥ 1 treatment with diuretic
agent (n = 807)
474 (37.0) 11 (39.3) 263 (49.3) 28 (66.7) 11 (45.8) < 0.001 < 0.001
≥1 treatment with
-blocker (n = 507)
320(25.0) 7 (25.0) 158 (29.6) 12 (28.6) 10 (41.7) 0.127 —
≥ 1 treatment with calcium
antagonist (n = 532)
322 (25.1) 14 (50.0) 157 (29.5) 18 (42.9) 8 (33.3) 0.002 0.003
≥ 1 treatment with central
antihypertensive agent
(n = 101)
51 (3.98) 2 (7.14) 42 (7.88) 5 (11.9) 1 (4.17) 0.003 < 0.001
Data are expressed in n (%); (0) GFR≥ 90mL/min per 1.73m2 or 60≤GFR≤ 89mL/min per 1.73m2 with none of the ﬁve renal disease markers (microalbuminuria, proteinuria, pathological
hematuria, pathological leukocyturia, morphological abnormalities at renal ultrasonography) during greater or equal to 3months. (1) 60≤GFR≤ 89 with at least one of the ﬁve
above-mentioned renal disease markers during greater or equal to 3months. (2) 30≤GFR≤ 59. (3) 15≤GFR≤ 29. (4) GFR < 15. ACE inhibitor: angiotensin-converting enzyme inhibitor;
A2RB: angiotensin II receptor blocker; P: the value of P is the result of the Chi-square test. P-trend: the value of P is the result of the Chi-square test for trend.
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[Figure 1. Use of ACE inhibitors without A2RBs, of A2RBs without
failure (GFR < 60mL/min per 1.73m2), with or without microalbum
is associated with an increase in morbidity and mortality
[16—18]. It is also of note that this survey was conducted
after the publication of the reference values for the esti-
mation of GFR based on serum creatinine by the Société
franc¸aise de biologie clinique and the Société franc¸aise de
néphrologie for the communication of laboratory results to
the patient’s physician. According to the results of our sur-
vey, there was no change in standard practices concerning
the referral of patients to a nephrologist following the pub-
lication of these criteria.
In our cohort, 70.5% of patients presenting with a GFR
inferior or equal to 89mL/min per 1.73m2 and 1.47% pre-
senting with a GFR between 60 and 89mL/min per 1.73m2
had had renal disease markers for more than threemonths.
Furthermore, the prevalence of patients for whom serum
creatinine was reported and who presented with renal
damage (GFR≤ 59mL/min per 1.73m2) was 31.4%. Among
these patients, 27.9% (n = 533) had moderate CRF, 2.20%
(n = 42) had severe CRF and 1.26% (n = 24) suffered from
end-stage renal failure. In France, the overall prevalence
of renal diseases is estimated at between two and three
million [19]. According to the REIN registry data, the over-
all crude incidence rate of CRF patients treated by dialysis
was 123 per million population (pmp) in 2003 in the seven
regions participating in the registry, and in 2005, it was
139 pmp in the thirteen participating regions [20,21]. In
the PHENOMEN study conducted in 2001 including 16,358
hypertensive patients treated by GP, which analyzed the
prevalence of renal dysfunction for 8650 of these patients
(mean age = 63± 12 years, 53% men) [10], 51% of patients
(4411) exhibited signs of renal failure, 28% (2422) had mild
renal failure (60≤GFR< 80mL/min), 22% (1903) had mod-
erate renal failure (30≤GRF < 60mL/min) and 1% (44) had
severe renal failure (GFR < 30mL/min). In a sample with a
similar mean age and male/female distribution, the results
s
•
•inhibitors, and of ACE inhibitors and A2RBs in patients with renal
and/or proteinuria.
f our study are slightly higher, suggesting a progression of
enal disease in France. Another French study conducted
mong hypertensive patients seen by cardiologists in pri-
ate practice reported ﬁgures comparable to ours with a
revalence of CRF deﬁned as a creatinine clearance inferior
o 60mL/min being 32%, and 61% when the threshold was
xed at 80mL/min. In this study, mild to moderate renal
ailure was underdiagnosed with 71% of patients being sub-
ectively considered as having normal renal function [9].
oreover, hypertensive patients with CRF did not show more
ardiovascular risk factors or comorbidities compared to
atients with normal renal function and the prevalences
f type 2 diabetes and hypercholesterolemia were similar in
oth groups. A British study reported a prevalence of CRF
f 1701 pmp, with an overrepresentation of men and older
atients when CRF was deﬁned by serum creatinine supe-
ior to 150mol/L [22]. In the United States, the incidence
f CRF is estimated at 6600 pmp, with one in 16 Americans
aving a creatinine clearance between 15 and 60mL/min
er 1.73m2 [23]. Recently, a study aiming to update the ﬁg-
res concerning the prevalence of CRF in the United States
y means of the latest NHANES studies referring to NHANES
999—2004, including 13,233 subjects aged 20 years or more
mean age = 46.2± 0.3 yrs), the prevalence of CRF stages
—4 was 13.1% and gave a GFR greater than or equal to
0mL/min per 1.73m2 for 40.7% of the population, a GFR
etween 60 and 89mL/min per 1.73m2 for 51.2%, a GFR
etween 30 and 59mL/min per 1.73m2 for 7.7% and a GFR
etween 15 and 29mL/min per 1.73m2 for 0.35% of subjects
24]. The differences between these results and those of our
tudy could be explained by the following facts:
our population is older;
our population was selected on the basis of blood pressure
criteria (130/80mmHg and treatment by an antihyperten-
sive drug);
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these authors use the MDRD formula for the calculation of
GFR [25].
We have shown that among patients for whom serum cre-
tinine had been measured, microalbuminuria was found
n only 14.6% and proteinuria in 9.6%. These results
iffer greatly from the MIRA survey, which aimed to
nvestigate the epidemiology of microalbuminuria among
atients with type 2 diabetes (563 patients of which 55%
en, mean age = 64.7± 11.2 years, duration of hypertension
10.5± 6.9 years). In total, 349 out of 510 patients (68%) had
lood pressure superior to 130/80mmHg and 51% presented
ith microalbuminuria greater than 30mg/L [28].
Our study shows that 31.4% of subjects included in the
urvey, that is one third of hypertensive patients seen by
P, present with renal failure. In this sub-group, approxi-
ately 92% of patients are being treated but in only 7% is
lood pressure successfully controlled. These results are in
ine with other French studies, showing that the control of
lood pressure in patients with CRF is poor with regard to
he recommendations for good clinical practice [10,26].
In our study, among the patients whose blood pressure
as superior to 130/80mmHg, many had a lowered GFR or
ven renal dysfunction (only 22 out of 1908 patients had
lood pressure inferior to 140/90mmHg, a normal renal
unction and were not taking any hypertensive medication).
hilst the JNC report VII claims that hypertensive patients
ith renal failure should be treated rather aggressively with
t least three antihypertensive drugs in order to achieve
blood pressure target of 130/80mmHg, analysis of ther-
peutic management of hypertension in our study shows
hat few patients beneﬁt from optimal treatment with 879
ut of 1908 (46.1%) taking only one antihypertensive drug.
oreover, 687 out of 879 (78.2%) of patients treated with
ntihypertensive medication maintained a blood pressure
uperior to 140/90mmHg (representing 36% of analyzed sub-
ects) and 184 out of 687 (26.8%) presented with CRF. These
esults are in line with those of the NHANES III study, in
hich hypertensive subjects with increased serum creati-
ine had a mean blood pressure of 147/77mmHg and 48%
ook only one hypertensive drug [27]. Another ﬁnding of the
HANES III study was that 3% of Americans had a raised serum
reatinine, 70% were hypertensive and 75% of these hyper-
ensive patients were being treated. Moreover, only 11% of
hese hypertensive patients had a blood pressure inferior to
30/85mmHg [27].
The principle factors permitting to slow down the
rogression of renal dysfunction, especially in chronic
lomerulopathies, are proteinuria and hypertension [8].
ACE inhibitors and A2RB are believed to have protective
ffects in patients with renal dysfunction and are thought
o slow the progression towards end-stage renal disease.
he beneﬁts are particularly evident in patients with or
ithout diabetes, presenting with proteinuria superior to
g per 24 h and they remain signiﬁcant to a lesser degree
hen proteinuria is inferior to 3 g per 24 h [8]. Taking this
nto account, ACE inhibitors and A2RB appear underused,
specially in hypertensive patients with renal failure. Con-
idering the prescription of ACE inhibitors and A2RB to the
9 diabetic patients with renal failure and microalbumin-
ria, 27.5% took ACE inhibitors, 43.5% took A2RB and 5.80%
ook both ACE inhibitors and A2RB. In the MIRA survey, 45%
i
q
o
t
iA. P.-Guérin et al.
f hypertensive patients were treated with ACE inhibitors
nd 35% with A2RB [28]. While our results are comparable
o those of the MIRA survey concerning the prescription of
2RB, the prescription of ACE inhibitors seems much lower
n our population, suggesting that the prescription of ACE
nhibitors could be higher in hypertensive diabetic patients
han in patients with renal failure.
Thus, it seems that the treatments at the disposition of
ractitioners are not used in an optimized way to lower
lood pressure and to slow the progression of renal dysfunc-
ion, while it has been clearly established that decreasing
lood pressure permits the slowing down of progression of
omplications in the long-term. These complications may
ot only affect the kidneys, but also the microvascular or
ven the macrovascular system and particularly cardiovas-
ular diseases.
This survey has limitations, notably concerning the col-
ection of data by GP in a registry, without carrying out any
ubsequent examinations. For this reason, serum creatinine
as reported for only 1959 of 2315 patients initially included
n the study, which does not rule out the possibility that the
56 patients without serum creatinine values might have
een diagnosed with renal failure. It is therefore possible
hat the prevalence of renal dysfunction in our study popula-
ion was underestimated because in 15.7% of patients, serum
reatinine was not available. In spite of these limitations,
ur study provides valuable information on a comprehen-
ive cohort from all over France. We are aware that the use
f another formula such as the MDRD formula would have
llowed a better estimation of renal clearance, particularly
n special populations such as obese or elderly patients.
owever, the Cockroft and Gault formula remains the most
ommon in scientiﬁc literature, enabling us to compare our
esults with those of other published studies.
onclusion
idney diseases must be searched for because they are
nitially asymptomatic and their early treatment has been
hown to delay the commencement of RRT and to lower
he risk of cardiovascular accidents [19]. As highlighted by
ourel and Ardaillou in their 2004 report, the screening of
RF must target at-risk populations, especially those suffer-
ng from AH [19].
The administration of an ACE inhibitor or an A2RB as ﬁrst
ine therapy seems essential particularly in the case of pro-
einuria. It must also be remembered that renal dysfunction
r proteinuria — which should be routinely tested for — are
ajor cardiovascular risk factors.
Our results show a high frequency of CRF in hypertensive
atients, which is in line with the results of other stud-
es conducted among GP. In patients whose GFR is inferior
o 60mL/min per 1.73m2, it is only possible to slow down
he deterioration of renal function. Yet these patients are
nsufﬁciently treated and despite the results of recent epi-
emiological studies, there seems to be no improvement
n the therapeutic management of these patients. Conse-
uently, efforts should be made to properly educate GP in
rder that they contribute to the early detection of CRF,
o better therapeutic management using in particular ACE
nhibitors and A2RB which have been proved to protect the
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kidneys in hypertensive patients, and to quicker referral of
patients to cardiologists and nephrologists.
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